ATRA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Atara Biotherapeutics Inc (ATRA) is not a good buy for a beginner, long-term investor with $50,000-$100,000 available for investment. The company is facing significant financial challenges, regulatory uncertainties, and insider/hedge fund selling trends. Despite a recent price increase, the lack of positive catalysts, poor financial performance, and bearish technical indicators make this stock a sell recommendation.
The MACD is positive at 0.379, indicating some bullish momentum, but the RSI at 75.737 is in the neutral zone. Moving averages show a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near resistance levels (R1: 5.522), suggesting limited upside potential.
Canaccord raised the price target to $25, citing a reasonable chance for FDA approval of tab-cel by January 2026, which could reinvigorate the pipeline.
The FDA recently rejected Atara's cell therapy tabelecleucel, highlighting regulatory uncertainty. Insiders and hedge funds are heavily selling, with insider selling up 685.89% in the last month and hedge fund selling up 192.53% last quarter.
In Q3 2025, revenue dropped by -91.41% YoY to $3.45M, net income fell by -80.36% YoY to -$4.3M, and EPS declined by -89.08% YoY to -0.32. While gross margin increased to 96.67%, the overall financial performance is weak.
Canaccord maintains a Buy rating with a raised price target of $25, citing potential FDA approval of tab-cel. However, this is a long-term catalyst with no immediate impact.
